An Oral BTK Pill Cut Relapses in Two Phase Three MS Trials With Full Data Still Unreleased
Novartis reported that remibrutinib, an oral BTK inhibitor, significantly reduced relapse rates compared to teriflunomide in two Phase 3 trials for relapsing multiple sclerosis, with no liver safety signals. Full data, including relapse rates and adverse events, will be presented in October 2026. The drug is not yet approved for MS.
How this was made
The 30-second read
Why it matters
The topline success could position Novartis as a contender in the oral MS market, pending detailed efficacy and safety data.
Market read
First indication of positive Phase 3 data for an oral MS therapy; relevance mainly to biotech investors.
What to watch
Potential competition from infused anti‑CD20 antibodies and regulatory scrutiny of liver safety.
Background
Novartis' remibrutinib is an oral BTK inhibitor previously approved for chronic urticaria; now being evaluated for MS.
Ticker impact
Novartis announced topline Phase 3 results showing its BTK inhibitor remibrutinib reduced relapse rates versus teriflunomide in MS trials.
Potential modest upside if full data confirms efficacy and safety.
First disclosure of trial success, but lack of numbers limits immediate pricing impact.
Market effects
May stimulate interest in oral BTK inhibitors for MS and related autoimmune markets.
US biotech sector could see modest attention; European markets less affected.
Limited to investors tracking MS therapeutics and biotech pipelines.
Counterpoint
Without quantitative data, the topline claim may be overstated; investors should wait for full results.
Key entities
- CompanyNovartis
Swiss pharmaceutical company reporting the trial results.
- DrugRemibrutinib
Oral BTK inhibitor under investigation for multiple sclerosis.
